Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer

European Respiratory Journal

Volumn 36, Issue 4, 2010, Pages 885-892

  Kumar, S ^a   Guleria, R ^a   Singh, V ^a   Bharti, A C ^b   Mohan, A ^a   Das, B C ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Biomarker; Chemotherapy; Response; Sensitivity; Specificity

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL FREE SYSTEM; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; HUMAN; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 77956487870     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00187909     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Gridelli C, Rossi A, Maione P. Treatment of non-small cell lung cancer: state of the art and development of new biological agents. Oncogene 2003; 22: 6629-6638.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-392.
5. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21: 2651-2657.
6. 18F- fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106.
7. de Geus-Oei LF, van der Heijden HF, Corstens FH, et al. Predictive and prognostic value of FDG-PET in non-small cell lung cancer: a systematic review. Cancer 2007; 110: 1654-1664.
8. Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006; 52: 1833-1842.
9. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
10. Gajalakshmi V, Hung RJ, Mathew A, et al. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in Southern India. Int J Cancer 2003; 107: 441-447.
11. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results in cancer treatment. Cancer 1981; 47: 207-214.
12. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta 2007; 1775: 181-232.
13. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46: 318-322.
14. Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the Nras gene in the blood plasma of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994; 86: 774-779.
15. Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994; 3: 67-71.
16. Kamat AA, Bischoff FZ, Dang D, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006; 5: 1369-1374.
17. Rago C, Huso DL, Diehl F, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007; 67: 9364-9370.
18. Holdenrieder S, Stieber P, von Pawel J, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin-19 fragments. Ann N Y Acad Sci 2006; 1075: 244-257.
19. Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 2008; 14: 7813-7821.
20. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as a prognostic marker in non-small cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22: 4157-4164.
21. Sozzi G, ConteD, LeonM, et al.Quantification of free circulatingDNA as a diagnosticmarker in lung cancer. J ClinOncol 2003; 21: 3902-3908.
22. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001; 61: 4675-4678.
23. Zitt M, Muller HM, Rochel M, et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers 2008; 25: 159-165.
24. Economidou-Karaoglou A, Brasseur F, Lans M, et al. Variations in serumalkaline DNase activity in rats during growth and treatment of tumors sensitive or resistant to therapy. Int J Cancer 1989; 43: 956-959.
25. Burlingame RW, Volzer MA, Harris J, et al. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996; 156: 4783-4788.
26. Gauthier VI, Tyler LN, MannikM. Blood clearance kinetics and liver uptake ofmononucleosomes inmice. J Immunol 1996; 156: 1151-1156.
27. Odaka C, Mizuochi T. Role of macrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells. J Immunol 1999; 163: 5346-5352.
28. Fournie GJ, Courtin JP, Laval F. Plasma DNA as a marker of cancerous cell death: investigation in patients suffering from lung cancer and in nude mice bearing human tumour. Cancer Lett 1995; 2: 221-227.
29. Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 2003; 105: 361-370.
30. Sozzi G, Roz L, Conte D, et al. Plasma DNA quantification in lung cancer computed tomography screening. Am J Respir Crit Care Med 2009; 179: 69-74.
31. van der Drift MA, Hol BE, Klaassen CH, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010; 68: 283-287.
32. Chorostowska-Wynimko J, Szpechcinski A. The impact of genetic markers on the diagnosis of lung cancer: a current perspective. J Thorac Oncol 2007; 2: 1044-1051.
33. Szpechcinski A, Struniawska R, Zaleska J, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 2008; 59: Suppl. 6, 675-681.
34. Sozzi G, Roz L, Conte D, et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005; 97: 1848-1850.
35. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009; 361: 1018-1020.
36. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008; 13: 14-20.